van Es-Johansson An
Known title: DirectorCIK: 0001795902
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Transaction History
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/9/2025 | View on chart |
| SVRA | ▲ Buy | Grant | 40,000 | $0 | 12/12/2024 | View on chart |
| SVRA | ▲ Buy | Grant | 22,500 | $0 | 12/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.